ClinicalTrials.gg
RecruitingNCT06536517Updated Jan 12, 2026

The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription.

A Phase 2 interventional study of Methadone in Fibroid Uterus, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 156 studies in Leiomyoma with a site in United States — 19 open to participants now, 29 under way, 3 of them phase 3. Leiomyoma · United States.

Planned enrollment
34th of 121
100 · median 57
Started
2025
with 7 others
Phase 2
19 of 156
2 open now
Primary completion
2026-12
later than 13 of 27 live
Registered
144th of 156
by date

Among the 156 studies in Leiomyoma with a site in United States, this one is the 34th largest by planned enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 13 of the 27 other live ones, and was the 144th registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

19 of the 156 studies in Leiomyoma with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Leiomyoma with a site in United States, or all of them as a file.
02

Study summary

Currently, there is a nationwide epidemic of opioid abuse and overdose deaths. One source of excess opioids is overprescribing in the postoperative period. This study aims to find the optimal pain medication plan during and after laparoscopic hysterectomy to eliminate long-term opioid use.

Given the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of Methadone, a longer opioid analgesics, intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries. The investigators hypothesize that this could minimize the need for additional post-operative and outpatient opioid prescriptions and decrease the adverse effects that are associated with the consumption, including new opioid abuse.

Intervention group will receive methadone intraoperatively while the other group would receive short-acting opioids (standard).

Read the detailed description

Problem:

The relief of moderate to severe postoperative pain in surgeries including abdominal surgeries continues to pose a major therapeutic dilemma. The traditional and most common therapy is the administration of short-acting opioid analgesics, intra-operative and post-operative, at intervals every 3-4 hours. However, the use of opioids with relatively short plasma half-lives at varying intervals may lead to various fluctuating drug concentrations in plasma, and side effects including respiratory, longer hospitalizations, delayed ambulation, inadequate pain relief and potential avenues for abuse. Identifying a more efficient and safer therapy for intraoperative pain analgesia can be helpful in controlling pain requirements in the post-operative setting.

In major inpatient and ambulatory surgeries, intraoperative single-dose methadone, through its unique pharmacology, has been shown to produce better analgesia, reduce opioid use and minimize adverse side effects compared with conventional repeated dosing of short-duration opioids. Additionally, methadone is theorized to be an N-methyl-D-aspartate (NMDA) receptor noncompetitive antagonist, which may contribute to its increase in analgesic potential as compared with fentanyl analogues. Finally, it has been shown to improve ambulation in the post operative anesthesia setting and pain control in chronic pain patients. The study of intra-operative methadone has not been extensively studied for gynecology surgeries, but one study has shown the decrease of mean opioid consumption post operatively after receiving one dose of intra-operative methadone compared to shorter acting opioids in same-day laparoscopic myomectomy. Given the increasing opioid abuse and over-prescription post-operatively, an effort should be made to determine whether one time dosing of longer opioid analgesics intra-operatively is an adequate potential in treating postoperative pain after hysterectomy surgeries and could minimize the need for additional post-operative and outpatient opioid prescriptions.

This study aims at addressing the requirement for postoperative opioid prescription after intraoperative longer acting vs shorter acting opioids in laparoscopic hysterectomy.

Hypothesis:

Single dose of intra-operative methadone is an adequate potential in treating post-operative pain after laparoscopic total hysterectomy surgeries, reducing the additional need for post-operative and outpatient opioid prescriptions and decreasing the adverse effects associated with opioid consumption.

Importance of research:

Given the increasing opioid abuse and over-prescription post-operatively, an effort must be made to determine whether one time dosing of longer opioid analgesics intraoperatively in conjunction with non-opioid multimodal medications is adequate to treat postoperative pain after laparoscopic hysterectomy. Additionally, this intervention may decrease the need for additional prescriptions or unscheduled patient contacts.

03

Conditions studied

  • Fibroid Uterus

Browse trials for

Keywords

  • hysterectomy
  • methadone
  • opioids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a uterus
  • Age 18 years old and above
  • Undergoing minimally invasive (laparoscopic or robotic) hysterectomy with ovarian preservation
  • Benign indications for hysterectomy
  • Agreeing to participate

Exclusion criteria

Exclusion Criteria:

  • Chronic pain syndromes patients including fibromyalgia
  • Patients currently on long-term (i.e. for more than three months) opioid use
  • Patients currently on agonist-antagonist medications (e.g. buprenorphine)
  • Patients taking a selective serotonin reuptake inhibitor or monoamine oxidase inhibitor
  • Conversion to laparotomy
  • Allergy or other to the prescribed medications such as methadone, fentanyl, acetaminophen or oxycodone
  • Severe Obstructive Sleep Apnea (OSA)
  • Pregnant/breastfeeding patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Methadone

    Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)

    Drug: Methadone

  • Other
    Short-Acting Opioid

    Standard intra-operative IV shorter acting opioids

    Drug: Methadone

Interventions

  • Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)

06

What researchers measure

Primary outcomes

  1. Total post-operative opioid requirements in oral morphine milligram equivalents (MME)

    Total post-operative opioid requirements in oral morphine milligram equivalents (MME) in first 7 post operative days.

    Time frame: 1 week

Secondary outcomes

  1. Mobility and satisfaction of analgesia

    Mobility and satisfaction of analgesia on post-operative day one and seven (binary question Y/N)

    Time frame: Post operative day 1, Post operative day 7

  2. Number of unplanned returns to emergency room/clinic or patient initiated phone call regarding pain

    Time frame: 1 week

  3. Overall satisfaction with pain control

    0-10 scale (0- no pain, 10-worst pain)

    Time frame: 1 week

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2024
First posted
Aug 5, 2024
StartActual
Mar 7, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06536517
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Mar 7, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Mostafa Borahay, MD, MBA, PhD
Contact
mboraha1@jhmi.edu
410-550-0337
Mostafa Borahay, MD, MBA, PhD
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion